Post-transcriptional editing of apolipoprotein B (apoB) mRNA is regulated by APOBEC1 (also designated human (or rat) small intestinal apolipoprotein B mRNA editing protein, HEPR or REPR) in hepatic cells to achieve a steady state proportion of edited and unedited RNA molecules. Two forms of apoB are known to circulate in the plasma of mammals. ApoB-100 is a protein primarily synthesized in the liver as a structural component of very low density lipoprotein particles. A truncated form of apoB-100, apoB-48, is synthesized in the small intestine and contains the amino-terminal 2,152 amino acids of the larger protein. This organ-specific partitioning of apoB production is the resultof RNA editing of a common apoB gene.
Formulation
1 mg/ml in 1X PBS; BSA free, sodium azide free
Host
Mouse
Immunogen Region
A portion of amino acids 592-689 from the human protein was used as the immunogen for the APOB antibody.
Isotype
Mouse IgG2b, kappa
Species Reactivity
Human
Note
Optimal dilution of the APOB antibody should be determined by the researcher.
Uniprot
P04114
Format
Purified
Purity
Protein G affinity chromatography
Storage
Store the APOB antibody at 2-8oC (with azide) or aliquot and store at -20oC or colder (without azide).
Applications
IHC-P
Description
Immunohistochemistry (FFPE): 1-2ug/ml for 30 minutes at RT